Chimerix’s (CMRX) Neutral Rating Reaffirmed at Wedbush

Chimerix (NASDAQ:CMRX)‘s stock had its “neutral” rating reissued by equities researchers at Wedbush in a note issued to investors on Wednesday,RTT News reports. They presently have a $8.55 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $7.00. Wedbush’s price target would indicate a potential upside of 1.48% from the stock’s previous close.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $8.55 price target (down from $11.00) on shares of Chimerix in a research note on Wednesday.

Chimerix Trading Up 69.9 %

NASDAQ CMRX traded up $3.47 during trading on Wednesday, reaching $8.43. The company’s stock had a trading volume of 104,896,018 shares, compared to its average volume of 1,913,809. The firm has a 50 day moving average price of $4.04 and a 200 day moving average price of $2.17. Chimerix has a 12 month low of $0.75 and a 12 month high of $8.44. The firm has a market capitalization of $757.71 million, a price-to-earnings ratio of -8.96 and a beta of 0.32.

Insider Buying and Selling

In related news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold 20,760 shares of company stock valued at $91,175 over the last quarter. 13.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Chimerix

A number of institutional investors have recently added to or reduced their stakes in CMRX. Bender Robert & Associates bought a new stake in Chimerix during the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC acquired a new stake in Chimerix in the 4th quarter valued at $59,000. Jane Street Group LLC bought a new stake in Chimerix during the 4th quarter worth approximately $62,000. Diadema Partners LP bought a new stake in shares of Chimerix in the 4th quarter worth $101,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Chimerix in the 4th quarter worth approximately $130,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.